India Won't Add Merck's COVID-19 Pill To National Treatment Protocol, Citing Safety Concerns
“Molnupiravir has major safety concerns including teratogenicity, mutagenicity, muscle and bone damage. If this drug is given, contraception must be done for three months as the child may have problems,”